Sanofi has entered into a global licensing and supply agreement with Ligand Pharmaceuticals to use Ligand's Captisol, a proprietary chemically modified cyclodextrin designed to optimize the solubility and stability of drugs, in the development and commercialization of Sanofi's SAR-125844, a MET kinase inhibitor.

Under the terms of the license, Sanofi will be responsible for all costs related to the program and Ligand will be eligible to receive potential milestone payments on future net sales and revenue from Captisol material sales. SAR-125844 recently competed a Phase I study in advanced/refractory solid tumor patients.

Source: Ligand Pharmaceuticals